Introduction
Significant efforts have been made to advance the field of new transition metal-based drugs, with significant breakthroughs in chemotherapy and other diseases. 1,2,3 Many organometallic drugs employ the ability of a metal to lose one or more electrons to form a soluble cationic complex in biological fluids and exacerbate their binding affinity as a cation with biological electron donors such as DNA and proteins. 4 Their targets can include carriers of vital molecules to body tissues or the provision of structural frameworks to the body. Metals are also embedded into catalytic proteins and facilitate various chemical reactions essential for life. 4 The synthesis of organometallic complexes for biological reasons attracts considerable interest due to their wide-ranging applications, such as amino acid synthesis. 5 Over the past two decades, interest has increased in the organogold complexes for their high medicinal activities. Their structural design with simple and potent ligands are key aspects of medicinal inorganic chemistry with uses targeting varied afflictions such as asthma, malaria, rheumatoid arthritis, HIV 6 and cancer. 7, 8 Furthermore, gold complexes are an excellent prototype for the rational design and development of novel and effective anti-cancer agents. 9 The activity of gold(I) complexes stems from their ability to penetrate the mitochondria and subsequently bind to the selenocysteine residue in thioredoxin reductase (TrxR). 10 TrxR is an enzyme usually over-expressed in tumour cells and involved in the growth and apoptosis of the cell. This overexpression hinders the apoptotic pathways. 7 The specificity of gold for mitochondria in cancerous cells was shown to arise from their hyperpolarisation, resulting in increased drug uptake compared to healthy cells, as we previously demonstrated. 3 11 We investigated the design flexibility provided by anti-cancer agents based on gold(I) and found that gold with an amide linkage exhibit substantial activity against mammalian breast cancer cells. 12 This discovery on the nature of the linkage to gold to retain substantial anti-cancer activity regardless of the structure of the ligands is crucial to outsmart cancer resistance and improve potency. Ligand design has since been focused on features that are complementing the gold apoptotic pathways against cancerous cells. We decided to investigate pyrazoles because of their high medicinal value. 13 They are important building blocks used in pharmaceutical and agrochemical industries. 14, 15, 16 Pyrazole is a special class of heterocyclic compound that can not only coordinate to enzymes (through van der Waals interactions) but also to metals, making them useful templates for the design of novel drugs. 13, 17 Their motif is also present in many biologically active compounds. 18 The structure/activity relationship (SAR) of pyrazoles alone has been extensively investigated and they were found to bind to a variety of receptors, enhancing the activity of many antiangiogenesis agents. 19 Pyrazoles have also shown great proapoptotic potential against lung cancer cell lines 20 as well as excellent cytotoxicity against cells carrying the p53 cancer mutation Y220C. 21 Pyrazolates and imidazolates substituted with deactivating groups were used to synthesise neutral azolate gold(I) phosphane complexes and were found to act as anti-cancer agents. 22 The choice of the substitution pattern was based on previous observations whereby substitution R 3 at the 4-position (scheme 1) seemed to stabilise binding to p53-Y220C through London interactions in a lipophilic pocket. 21 Substitution at the N2-position and N1-positions A closer look at the X-ray diffraction of the protein shows further possible interactions, notably Debye and Keesom dipolar interactions with the carbonyl at P153 and P152. We decided to include a range of substitutive functional groups (pyridine, bromophenyl, nitrile and bromine) to verify any impacts of such interactions on the activity of our complexes. The inhibitory properties of neutral gold(I) triphenylphosphine complexes on E. coli dihydrofolate reductase was found to be toxic against different human cancer cell lines. 23 In our search for dual action orthogonal drug and based on our previous observations of the reactivity of gold amide complexes on cancer cells, 12 we decided to investigate a different class of amide ligands that is known to be active against cancer cells, yet with a different pathway to that of gold(I) alone, to further the applicability of anticancer drug candidates based on a goldnitrogen bond. We investigated in this paper the role of delocalised cationic gold pyrazole complexes against the HepG2 human liver cancer cell line. HepG2 is a cell line widely used as a model system for hepatocyte cancers. Hepatocellular carcinomas are notoriously difficult to treat due to the ease at which they develop resistance to most common chemotherapeutic drugs. 24
Results and Discussion

Synthesis of the complexes
We herein report on the complexation of pyrazole ligands 1-5 to form an array of pyrazole gold(I) complexes 6-10 (Scheme 1, Table  1 ).
Scheme
1.
Regioselective synthesis of pyrazole triphenylphosphinegold(I) perchlorates 6-10.
The synthesis of these complexes is commonly hampered by long reaction times (two days and more) 25 and so our procedure was optimised to give rapid, facile and reproducible results. The successful synthesis of the intermediary cationic triphenylphosphinegold perchlorate was systematically assessed by 31 P NMR, and a single peak between 27 and 29 ppm, depending on the concentration, was observed. All complexes were characterised by 1 H, 13 C and 31 P NMR and their positiveion ESI-MS displayed the [M] + peaks in agreement with the calculated isotopic pattern. Minor partial disproportionation to homoleptic complexes and to [Au(PPh3)2] + was observed for complex 6 (less than 0.1%) and for complex 9 (5%). Unfortunately, satisfactory crystals could not be grown for complex 6, so its structure could not be ascertained. However, based on our observation for complexes where R 1 = H, it is highly probably that the regioselectivity should favour complex 6a over 6b. The results are collated in table 1. 
X-Ray diffraction
Suitable crystals for x-ray crystallography of complexes 7-10 were obtained by slow evaporation of dichloromethane and nhexane in a [1:1] ratio although the crystals for complex 6 were too small for x-ray diffraction. The crystals were characterised by X-ray crystallography to confirm the atom connectivity and molecular geometry. The main results of the crystal structure determinations are reported in Table 2 . Table 3 lists some selected bond lengths and angles of the four complexes. (5) 1.367 (11) N1 -C5 1.337(10), 1.330 (10) 1.317 (16) 1.325 (6), 1.333 (6) 1.317 (12) N2 -C3 1.338(10), 1.355 (9) 1.354 (15) 1.351 (6), 1.343 (6) 1.357 (12) C3 -C4 1.393(11), 1.405 (10) 1.382 (16) 1.402 (6), 1.407 (6) 1.398 (13) C4 -C5 1.412(11), 1.396 (11) 1.379 (16) 1.384 (6), 1.383 (6) 1.395 (13) C3 -N6 1.393(10), 1.410 (10) 1.327 (17) 1.342 (6), 1.337 (6) 1.340 (13) C4 -C7 1.477(10), 1.470 (11) 1.484 (16) 1.419 (6), 1.418(6) C4 -Br7 1.859(9) P -C9
1.815(8), 1.817 (7) 1.803 (12) 1.812(4), 1.814 (4) 1.812 (9) P -C10 1.818(8), 1.811 (7) 1.805 (12) 1.813 (5), 1.801 (5) 1.816 (9) P -C11 1.808 (7), 1.816 (7) 1.795 (15) 1.819(4), 1.805 (4) 1.813 (9) N1 -Au -P 176.68 (19) 176.01 (11), 176.98 (11) 175.3(2) Figure 1 shows the structures in ORTEP format with the selected numbering scheme. Please do not adjust margins Please do not adjust margins goniometer head of a Rigaku Oxford Diffraction Gemini E diffractometer equipped with an EOS CCD area detector, data collection was performed at 173K. Complex 7a was collected on a Rigaku Oxford Diffraction 007HFM/AFC11 diffractometer equipped with a Saturn 944+ CCD area detector at 100K. All complexes were collected with monochromated CuKα radiation, by means of ω-scans. The diffraction intensities were corrected with respect to Lorentz and polarization effects. Empirical multi-scan absorption corrections, using equivalent reflections, were also performed with the scaling algorithm SCALE3 ABSPACK. Raw data collection, data reduction and refinalisation were carried out with the CrysAlisPro software. All complexes were solved by means of the intrinsic phasing method in SHELXT 2623 and refined by full-matrix least squares methods based on Fo 2 with SHELXL 27 in the framework of the OLEX2 28 software. In the last cycles of refinement all nonhydrogen atoms were refined anisotropically; hydrogen atoms were placed and refined as riding atoms with their isotropic displacement parameters set to 1.2 times the Ueq of the parent atom. The best crystal of complex 7a necessitated the collection on the Rigaku 007HFM due to its small size. In complex 8a, there is a small amount of disorder relating to the ligand binding through N2 or N1. The amount of disorder was too low to model satisfactorily, so this has been left unmodelled. The molecular structures of all complexes contained a two-coordinate Au centre with expected Au-P (2.2-2.4Å) and Au-N (2.0-2.2Å) distances and linear coordination irrespective of the state of molecularity in the crystal (Table 3 ). 11 The Au-P were in very good agreement with 2.25 Å reported by Keter et al 29 and 2.26 Å results of Cambridge Structural Database (CSD). 29 The perchlorate molecule was included in the lattice of the complexes 7-10 and CH2Cl2 was present only in the lattice of complex 10b. These display H-bonding to the NH2 and the endocyclic NH when R 1 =H. Ligand 1 has a pyridine at the fourth position, which provides another possible point of attachment compared to others. There is four possibilities for the point of attachment to gold (I). Therefore, four peaks were expected by 31 P NMR but only one peak at 30.0 ppm was observed indicating that there is only one possible linkage. Ligand 2 is a pyrazole with a bromophenyl at position 4 with three possible points of attachment but only one peak at 31.0 ppm was observed. X-ray crystallography also confirmed one linkage. The point of attachment was the nitrogen at the position one replacing the proton in that position but leaving a positive charge on the nitrogen ligand 3 has a similar structure to ligand 2 but with a methyl group at position three. Three points of attachment were also possible but the 31 P NMR indicated a single attachment point to gold (I) by given only one peak at 31.50 ppm. X-ray result also confirmed the single point of attachment but indicated that complex 8a is a regioisomer with a positive charge on the nitrogen in position 1. Ligand 4 has a cyano group at position four and an ethyl alcohol at position two given different likely point of attachment. However, 31 P NMR of the complex gave a single peak at 29.7 ppm indicating a single point of attachment to gold (I). X-ray diffraction indicated that complex 9b is a regioisomer with only one point of attachment to gold (I). Ligand 5 has a bromo substituent at position 4 and a methyl group at position one. 31 P NMR indicated only one point of attachment with a single peak at 30.0 ppm and attested to by the x-ray diffraction study. The point of attachment was at position 2. Complex 10b is non regioisomeric.
Cell viability assays
The biological activity of the complexes were assessed after dilution in DMSO/H2O (10% v/v) and addition to HepG2 cells. Assays were performed in 96-well plates using the Promega CellTiter-Blue assay as an endpoint method with a 2-hour incubation with the assay reagent. This assay measures cell viability and is based upon the ability of living cells to convert a redox dye (resazurin) into a fluorescent product (resorufin). Each well received 90 μL of cell suspension at a density of 22,500 cells per well and was cultured overnight (at 37 °C/5% CO2 humidified air) before 10 μL of the test sample was added. The experiments were set up in triplicate. The mock control wells received 90 μL of cell suspension and 10 μL of the appropriate buffer (DMSO/H2O). Wells that contained just 100 μL of cell culture medium served as background fluorescence controls. Fluorescent readings were taken using the GloMax-Multi Detection System (Promega).
The five complexes shown in Table 1 all indicated that they possessed reasonable activity against this cell line in a preliminary screen (data not shown). To confirm this activity various doses were then tested alongside their respective uncomplexed ligands. Figure 2 shows that even at the lowest dose tested (20 μM) all of the complexes showed high activity. In contrast the free ligands showed no significant activity at the same concentrations. Due to the high level of activity observed, further dilutions were made and tested (Figure 3) . These data indicate that complexes 7a, 8a, 9b and 10a remain highly toxic at 2 μM while 6 is significantly less toxic at this concentration. IC50 values were calculated as 1.75 μM (6), 0.19 μM (7b), 0.31 μM (8b), 0.13 μM (9a) and 0.23 μM (10a). 
Conclusions
Five new monocationic pyrazolium gold complexes 6-10 have been prepared in excellent yields and the substitution pattern did not seem to have a notable effect on their activity against the cancer cell line described herein. This flexibility in the design is desirable when fine tuning structural motifs for druggable applications. The regioselectivity of the complexation was found to be dependent on the substitution pattern on the endocyclic nitrogen N 1 , favouring the complexation of the nitrogen proximal to the 5-amino group when R 1 = H. All compounds are highly active against HepG2 cancer cells and display activity in the submicromolar range comparable to our previous work on gold complexes and breast cancer cell lines. 3 Futhermore their efficacy compares well to other chemotherapeutic drugs on this cell line 30 including Doxorubicin (IC50 1.1 μM) and Cisplatin (IC50 15.9 μM) Hepatocellular carcinomas readily acquire resistance to chemotherapeutic drugs -usually through the expression of a multidrug efflux pump. It is unknown whether these mechanisms would prevent the action of our gold amides or whether they have potential in treating resistant cells. This work therefore provides strategic tools to investigate such avenues of research.
